“がん、胎児の異常、およびその他の遺伝子異常をスクリーニングするための大量の遺伝子スクリーニング検査。さまざまな調査研究、個別化医療、消費者向け遺伝子検査の次世代スクリーニングの増加傾向が、遺伝子検査市場の成長を後押ししています。”
世界の遺伝子検査市場は、2022 年の xx0 億ドルから 2027 年までに xx0 億ドルに達し、CAGR は xx% になると予想されます。この市場の成長要因としては、遺伝性疾患の有病率の増加、癌の症例の増加、新生児の遺伝的異常などがあります。がんをスクリーニングするための遺伝子検査に対する意識の高まり、さまざまな遺伝病の研究のための次世代シーケンシング (NGS) の使用の増加に対する出生前遺伝子スクリーニングが、市場の成長を後押ししています。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.4 ECOSYSTEMS ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 PRICING ANALYSIS
6 GENETIC TESTING MARKET, BY PRODUCT?
6.1 INTRODUCTION
6.2 CONSUMABLES
6.3 EQUIPMENT
6.4 SOFTWARE AND SERVICES
6.5 COVID-19 IMPACT ANALYSIS
7 GENETIC TESTING MARKET, BY TECHNOLOGY?
7.1 INTRODUCTION
7.2 NEXT-GENERATION SEQUENCING
7.3 POLYMERASE CHAIN REACTION
7.4 FLUORESCENCE IN SITU HYBRIDIZATION
7.5 CHEMILUMINESCENCE IMMUNOASSAY
7.6 OTHER TECHNOLOGIES
7.7 COVID-19 IMPACT ANALYSIS
8 GENETIC TESTING MARKET, BY TESTING TYPE?
8.1 INTRODUCTION
8.2 PREDICTIVE TESTING AND PRESYMPTOMATIC TESTING
8.3 CARRIER TESTING
8.4 PRENATAL AND NEWBORN TESTING
8.5 PREIMPLANTATION TESTING
8.6 DIAGNOSTIC TESTING
8.7 PHARMACOGENOMIC TESTING
8.8 NUTRIGENOMIC TESTING
8.9 FORENSIC TESTING
8.10 COVID-19 IMPACT ANALYSIS
9 GENETIC TESTING MARKET, BY METHODS?
9.1 INTRODUCTION
9.2 MOLECULAR GENETIC TESTING
9.3 CHROMOSOMAL GENETIC TESTING
9.4 BIOCHEMICAL GENETIC TESTING
9.5 OTHERS (IF ANY)
9.6 COVID-19 IMPACT ANALYSIS
10 GENETIC TESTING MARKET, BY END USERS?
10.1 INTRODUCTION
10.2 HOSPITALS
10.3 CLINICAL LABORATORIES
10.4 OTHERS (IF ANY)
10.5 COVID-19 IMPACT ANALYSIS
11 GENETIC TESTING MARKET, BY REGION?
11.1 INTRODUCTION
11.2 EUROPE
11.2.1 ITALY
11.2.2 GERMANY
11.2.3 FRANCE
11.2.4 UK
11.2.5 SPAIN
11.2.6 REST OF EUROPE
11.3 NORTH AMERICA
11.3.1 US
11.3.2 CANADA
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.6 MIDDLE EAST AND AFRICA
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES
12.1 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY
12.2 MARKET SHARE ANALYSIS (2021, % OF USD MILLION)
12.3 COMPETITIVE SCENARIO
12.3.1 PRODUCT LAUNCHES AND APPROVALS
12.3.2 COLLABORATIONS
12.3.3 EXPANSIONS
12.3.4 ACQUISITIONS
12.3.5 OTHER DEVELOPMENTS
12.4 COMPETITIVE LEADERSHIP MAPPING
12.4.1 VENDOR INCLUSION CRITERIA
12.4.2 STARS
12.4.3 EMERGING LEADERS
12.4.4 PERVASIVE
12.4.5 EMERGING COMPANIES
13 COMPANY PROFILES
(Business overview, Products offered, Recent developments)*
13.1 F. HOFFMANN-LA ROCHE LTD.
13.2 ABBOTT LABORATORIES
13.3 THERMO FISHER SCIENTIFIC, INC.
13.4 AGILENT TECHNOLOGIES, INC.
13.5 BIO-RAD LABORATORIES, INC.
13.6 ILLUMINA, INC.
13.7 QIAGEN
13.8 SIEMENS HEALTHINIER
13.9 DANAHER CORPORATION
13.10 HOLOGIC, INC.
13.11 PERKINELMER INC.
13.12 MYRIAD GENETICS INC.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
